# Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

> **NCT00939770** · PHASE1,PHASE2 · COMPLETED · sponsor: **Children's Oncology Group** · enrollment: 122 (actual)

## Conditions studied

- Recurrent Childhood Anaplastic Large Cell Lymphoma
- Recurrent Malignant Solid Neoplasm
- Recurrent Neuroblastoma
- Refractory Anaplastic Large Cell Lymphoma
- Refractory Malignant Solid Neoplasm
- Refractory Neuroblastoma

## Interventions

- **DRUG:** Crizotinib
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT00939770
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09-21
- **Primary completion:** 2018-12-31
- **Final completion:** 2018-12-31
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2020-06-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00939770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00939770, "Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00939770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*